Myeloproliferative neoplasms trials in China

In China 30 Also abroad 210

30 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Where
Beijing, Changchun, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nantong, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Yantai
Age
18 years and over
People
460 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Xian, Zhengzhou
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
No phaseNot yet taking people in China
A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis
Where
Nantong
Age
18 years and over
People
80
Run by
Affiliated Hospital of Nantong University
See details and how to joinNCT07925632
No phaseNot yet taking people in China
Jaktinib in Ruxolitinib-Treatment Failure Myelofibrosis: A Multicenter, Prospective, Real-World Observational Study
Where
Nantong
Age
18 years and over
People
80
Run by
Affiliated Hospital of Nantong University
See details and how to joinNCT07925671
Phase 1Taking people
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Where
Beijing, Hangzhou, Tianjin
Age
18 years and over
People
300 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00
Phase 1/2Taking people
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
Where
Shanghai
Age
18 years and over
People
10
Run by
Ruijin Hospital
See details and how to joinNCT07883382
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Lanzhou, Nanchang, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
No phaseTaking people
Haplo-HSCT for Myelofibrosis
Where
Beijing
People
39
Run by
Peking University People's Hospital
See details and how to joinNCT06674382
Phase 1Taking people
Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis
Where
Zhengzhou
Age
18 days and over
People
20
Run by
Henan Cancer Hospital
See details and how to joinNCT07802405
Phase 1Taking people
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
Where
Tianjin
Age
18 years to 75 years
People
90
Run by
BeBetter Med Inc
See details and how to joinNCT07012109
Phase 2Taking people
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Where
Tianjin
Age
18 years and over
People
60
Run by
Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT07232290
Phase 3Taking people
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Where
Chengdu, Tianjin
Age
18 years to 80 years
People
105
Run by
Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT07317700
Phase 2Taking people
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis
Where
Chengdu, Tianjin
Age
18 years to 80 years
People
64
Run by
Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT07443306
Phase 2Taking people
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
Where
Cangzhou, Changchun, Changzhi, Chengde, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Nanjin, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Ürümqi, Wuhan, Xi’an, Xingtai, Zhengzhou, Zhuzhou
Age
18 years and over
People
51
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07551427
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Tianjin
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
No phaseTaking people
A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
Where
Beijing
Age
18 years and over
People
30
Run by
Duan Minghui
See details and how to joinNCT07445893
Phase 2/3Not yet taking people in China
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Where
Guangzhou
Age
18 years to 65 years
People
196
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT07539779
Phase 1Taking people
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
Where
Jinan, Luoyang
Age
18 years to 75 years
People
24
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07480824
No phaseTaking people
National Longitudinal Cohort of Hematological Diseases
Where
Tianjin
People
2,300
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04645199
No phaseTaking people
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
Where
Hangzhou
Age
18 years to 80 years
People
57
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06164561
Phase 1/2Taking people
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
Where
Cangzhou, Changchun, Changzhi, Chengde, Guangzhou, Harbin, Hohhot, Nanning, Shanghai, Tai’an, Tangshan, Tianjin, Ürümqi, Wuhan, Wuxi, Xi'an, Xingtai, Zhengzhou
Age
18 years and over
People
92
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06122831
Phase 2Taking people
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Where
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
Age
18 years and over
People
27
Run by
Xiamen Amoytop Biotech Co., Ltd.
See details and how to joinNCT06552429
Phase 1Taking people
A Study of GLB-001 in Patients With Myeloid Malignancies
Where
Beijing, Chongqing, Hangzhou, Hefei, Nanchang, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wenzhou, Wuhan, Zhengzhou
Age
18 years and over
People
108
Run by
Hangzhou GluBio Pharmaceutical Co., Ltd.
See details and how to joinNCT06378437
Phase 1Taking people
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Where
Hangzhou, Nanchang, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
108
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT06752746
No phaseTaking people
Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia
Where
Chengdu
Age
1 year to 3 years
People
90
Run by
West China Second University Hospital
See details and how to joinNCT06881056